AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
-
AbbVie: We Can Win Race Against Gilead Sciences, Inc. for First New Hepatitis C Drugs
6/14/2013
-
AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination With HUMIRA (adalimumab) for Rheumatoid Arthritis
6/13/2013
-
AbbVie Jumps Into $11.4 Million Series B for Avaxia Biologics, Inc.
6/7/2013
-
AbbVie to Participate in 34th Annual Goldman, Sachs & Co. Global Healthcare Conference
6/5/2013
-
The AbbVie Culture Change Continues: 100 Scientists Will be Laid Off
6/3/2013
-
AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
6/3/2013
-
AbbVie Announces Market Availability of New CREON® (Pancrelipase) 36,000 Lipase-unit Capsules for Patients With Exocrine Pancreatic Insufficiency
5/30/2013
-
AbbVie to Participate in 2013 Jefferies and Co. Global Healthcare Conference
5/28/2013
-
How Much?! AbbVie Raises Niaspan Price Despite Study Failures
5/24/2013
-
AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients With Diabetic Nephropathy
5/20/2013
-
AbbVie, Galapagos NV Ink $50 Million Crohn's Disease Pact
5/17/2013
-
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
5/16/2013
-
Alvine Pharmaceuticals, Inc. Lands $70 Million From AbbVie for Celiac Disease Drug
5/15/2013
-
AbbVie and Alvine Pharmaceuticals, Inc. to Collaborate on Investigational Oral Therapy for Celiac Disease
5/14/2013
-
A Culture Change? AbbVie R&D to Retire
5/14/2013
-
AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
5/7/2013
-
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation From the FDA
5/6/2013
-
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation
5/6/2013
-
European Medicines Agency Ordered Not to Release AbbVie's Trial Data, for Now
5/2/2013
-
AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students With Cystic Fibrosis
5/2/2013